MX9100160A - Procedimiento para preparar un medicamento que contiene flupirtina como sustancia activa para combatir contracturas musculares - Google Patents

Procedimiento para preparar un medicamento que contiene flupirtina como sustancia activa para combatir contracturas musculares

Info

Publication number
MX9100160A
MX9100160A MX9100160A MX9100160A MX9100160A MX 9100160 A MX9100160 A MX 9100160A MX 9100160 A MX9100160 A MX 9100160A MX 9100160 A MX9100160 A MX 9100160A MX 9100160 A MX9100160 A MX 9100160A
Authority
MX
Mexico
Prior art keywords
fight
preparing
procedure
active substance
product containing
Prior art date
Application number
MX9100160A
Other languages
English (en)
Spanish (es)
Inventor
Michael Lobisch
Ralph Venhaus
Bernd Nickel
Istvan Szelenyi
Jurgen Engel
Peter Emig
Original Assignee
Asta Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Pharma Ag filed Critical Asta Pharma Ag
Publication of MX9100160A publication Critical patent/MX9100160A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Golf Clubs (AREA)
  • Details Of Television Scanning (AREA)
  • Paints Or Removers (AREA)
MX9100160A 1990-07-14 1991-07-10 Procedimiento para preparar un medicamento que contiene flupirtina como sustancia activa para combatir contracturas musculares MX9100160A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4022442 1990-07-14
IN421CA1991 IN172468B (cg-RX-API-DMAC7.html) 1990-07-14 1991-06-04

Publications (1)

Publication Number Publication Date
MX9100160A true MX9100160A (es) 1992-02-28

Family

ID=25895002

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9100160A MX9100160A (es) 1990-07-14 1991-07-10 Procedimiento para preparar un medicamento que contiene flupirtina como sustancia activa para combatir contracturas musculares

Country Status (30)

Country Link
US (2) US5162346A (cg-RX-API-DMAC7.html)
EP (2) EP0467164B1 (cg-RX-API-DMAC7.html)
KR (1) KR0182811B1 (cg-RX-API-DMAC7.html)
CN (1) CN1070700C (cg-RX-API-DMAC7.html)
AT (2) ATE206919T1 (cg-RX-API-DMAC7.html)
AU (1) AU634073B2 (cg-RX-API-DMAC7.html)
CA (1) CA2046943C (cg-RX-API-DMAC7.html)
CZ (1) CZ280879B6 (cg-RX-API-DMAC7.html)
DE (3) DE59107331D1 (cg-RX-API-DMAC7.html)
DK (2) DK0659410T3 (cg-RX-API-DMAC7.html)
EG (1) EG19814A (cg-RX-API-DMAC7.html)
ES (2) ES2164111T3 (cg-RX-API-DMAC7.html)
GR (1) GR3019179T3 (cg-RX-API-DMAC7.html)
HR (1) HRP920667B1 (cg-RX-API-DMAC7.html)
HU (1) HU206973B (cg-RX-API-DMAC7.html)
IE (1) IE74688B1 (cg-RX-API-DMAC7.html)
IL (1) IL98810A (cg-RX-API-DMAC7.html)
IN (1) IN172468B (cg-RX-API-DMAC7.html)
LT (1) LT3593B (cg-RX-API-DMAC7.html)
LV (1) LV10048B (cg-RX-API-DMAC7.html)
MC (1) MC2272A1 (cg-RX-API-DMAC7.html)
MX (1) MX9100160A (cg-RX-API-DMAC7.html)
NO (1) NO912758L (cg-RX-API-DMAC7.html)
NZ (1) NZ238940A (cg-RX-API-DMAC7.html)
PT (1) PT98291B (cg-RX-API-DMAC7.html)
RO (1) RO108220B1 (cg-RX-API-DMAC7.html)
RU (1) RU2070408C1 (cg-RX-API-DMAC7.html)
SI (1) SI9111227B (cg-RX-API-DMAC7.html)
SK (1) SK279567B6 (cg-RX-API-DMAC7.html)
ZA (1) ZA915466B (cg-RX-API-DMAC7.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59307753D1 (de) * 1992-03-11 1998-01-15 Asta Medica Ag Tabletten, Granulate und Pellets mit hohem Gehalt an Wirkstoffen für hochkonzentrierte, feste Darreichungsformen
DE4319649A1 (de) * 1993-03-18 1994-09-22 Asta Medica Ag Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe
DE4327516A1 (de) * 1993-08-17 1995-02-23 Asta Medica Ag Primäre und sekundäre neuroprotektive Wirkung bei neurodegenerativen Erkrankungen von Flupirtin
GB9426079D0 (en) * 1994-12-23 1995-02-22 Orion Yhtymae Oy A gelatine capsule
DE19541405A1 (de) * 1995-11-07 1997-05-15 Asta Medica Ag Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen, die mit einer Beeinträchtigung des hämatopoetischen Zellsystems einhergehen
US6284794B1 (en) 1996-11-05 2001-09-04 Head Explorer Aps Method for treating tension-type headache with inhibitors of nitric oxide and nitric oxide synthase
US6610324B2 (en) * 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
JP2003530308A (ja) * 1999-08-03 2003-10-14 アーヴェーデー．ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディートゲゼルシャフト 犬および猫の退行性関節疾患に起因する痛みを軽減するためのフルピルチンの使用
US6821995B1 (en) 1999-12-01 2004-11-23 Duke University Method of treating batten disease
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
RU2213565C1 (ru) * 2002-06-24 2003-10-10 Общество с ограниченной ответственностью "Паркинфарм" Способ лечебного воздействия на организм пациента при лечении болезни паркинсона
DE10255415A1 (de) * 2002-11-28 2004-06-09 Bayer Healthcare Ag Dermale Applikation von Flupirtin
DE10327674A1 (de) 2003-06-20 2005-01-05 Awd.Pharma Gmbh & Co. Kg Injizierbare Darreichungsform von Flupirtin
US20050089559A1 (en) 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
DE102004001558A1 (de) * 2004-01-10 2005-08-18 Bayer Healthcare Ag Arzneimittel zur topischen Applikation bei Tieren
US20050196461A1 (en) * 2004-01-14 2005-09-08 Udell Ronald G. Ceramide formulations suitable for oral administration
KR20060124731A (ko) * 2004-01-29 2006-12-05 뉴로몰레큘라 파마슈티칼스, 인코포레이티드 중추신경계-관련 질환 치료용 ｎｍｄａ 수용체 길항제 및ｍａｏ-억제제 또는 ｇａｄｐｈ-억제제의 배합물
US20050220862A1 (en) 2004-03-31 2005-10-06 Bernstein Joel E Compositions with reduced hepatotoxicity
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
EP1688141A1 (en) * 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
PL1874282T3 (pl) 2005-04-06 2011-04-29 Adamas Pharmaceuticals Inc Sposoby i kompozycje do leczenia zaburzeń OUN
CA2650853A1 (en) * 2006-05-02 2007-11-15 Chris Rundfeldt Potassium channel activators for the prevention and treatment of dystonia and dystonia-like symptoms
US7960436B2 (en) * 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
PL2061465T3 (pl) * 2006-08-23 2014-03-31 Valeant Pharmaceuticals Int Pochodne 4-(N-azacykloalkilo) anilidów jako modulatory kanałów potasowych
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
ATE538084T1 (de) * 2006-11-28 2012-01-15 Valeant Pharmaceuticals Int Bicyclische 1,4-retigabin-analoga als kaliumkanalhemmer
US20080279930A1 (en) * 2007-05-07 2008-11-13 Bernd Terhaag Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
CA2694887A1 (en) * 2007-08-01 2009-02-05 Henriette Husum Bak-Jensen Use of kncq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
ES2347119B2 (es) * 2009-04-22 2011-04-28 Universidad De Santiago De Compostela Nanocapsulas de poliarginina.
DE102010030053A1 (de) 2010-06-14 2011-12-15 Awd.Pharma Gmbh & Co.Kg Injizierbare Darreichungsform von Flupirtin
JP6251667B2 (ja) * 2014-06-03 2017-12-20 アサヒカルピスウェルネス株式会社 錠剤型即放性製剤及びその製造方法
DE102017007385A1 (de) 2017-08-02 2019-02-07 Christoph Hoock Maleatfreie feste Arzneimittelformen
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
CN114667146A (zh) 2019-11-08 2022-06-24 泽农医药公司 治疗抑郁症的方法
MX2023009314A (es) 2021-02-09 2023-08-16 Xenon Pharmaceuticals Inc Apertura del canal de potasio dependiente de voltaje para usarse en el tratamiento de la anhedonia.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1795858C2 (de) 1968-07-19 1979-01-11 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt Benzylaminopyridine
DE3133519A1 (de) 1980-09-13 1982-06-09 Degussa Ag, 6000 Frankfurt "2-amino-3-carbethoxyamino-6-(p-fluor-benzylamino)-pyridin-maleat"
ATE46265T1 (de) * 1985-01-23 1989-09-15 Asta Pharma Ag Synergistische kombination von flupirtin und nicht-steroidalen antiphlogistika.
DE3604575A1 (de) 1985-02-23 1986-08-28 Degussa Ag, 6000 Frankfurt Kombination von flupirtin und anticholinergisch wirkenden spasmolytika
ATE43789T1 (de) * 1985-02-23 1989-06-15 Asta Pharma Ag Kombination von flupirtin und anticholinergisch wirkenden spasmolytika.
FI855016L (fi) * 1985-06-28 1986-12-29 Degussa Synergistisk kombination av flupirtin och 4-acetamido-fenol.

Also Published As

Publication number Publication date
IL98810A0 (en) 1992-07-15
GR3019179T3 (en) 1996-06-30
LV10048A (lv) 1994-05-10
RO108220B1 (ro) 1994-03-31
DE4122166A1 (de) 1992-01-16
US5284861A (en) 1994-02-08
SI9111227B (sl) 2000-12-31
KR0182811B1 (ko) 1999-05-01
AU8040391A (en) 1992-01-16
AU634073B2 (en) 1993-02-11
HU206973B (en) 1993-03-01
MC2272A1 (fr) 1993-06-23
PT98291A (pt) 1992-05-29
NO912758D0 (no) 1991-07-12
IL98810A (en) 1996-01-19
EP0467164B1 (de) 1996-01-31
LV10048B (en) 1995-06-20
ES2082887T3 (es) 1996-04-01
EP0659410A2 (de) 1995-06-28
SK279567B6 (sk) 1999-01-11
EP0467164A3 (en) 1992-04-15
ATE133564T1 (de) 1996-02-15
DE59109222D1 (de) 2001-11-22
KR920002147A (ko) 1992-02-28
LT3593B (en) 1995-12-27
CZ280879B6 (cs) 1996-04-17
IE912451A1 (en) 1992-01-15
ZA915466B (en) 1992-04-29
HUT59313A (en) 1992-05-28
CN1058716A (zh) 1992-02-19
IE74688B1 (en) 1997-07-30
ATE206919T1 (de) 2001-11-15
PT98291B (pt) 1999-01-29
NZ238940A (en) 1997-05-26
EP0659410B1 (de) 2001-10-17
EP0659410A3 (de) 1995-10-25
CA2046943A1 (en) 1992-01-15
US5162346A (en) 1992-11-10
CS210191A3 (en) 1992-02-19
IN172468B (cg-RX-API-DMAC7.html) 1993-08-14
DE59107331D1 (de) 1996-03-14
CA2046943C (en) 1996-03-12
NO912758L (no) 1992-01-15
SI9111227A (en) 1995-06-30
HRP920667A2 (en) 1996-10-31
ES2164111T3 (es) 2002-02-16
DK0467164T3 (da) 1996-03-04
DK0659410T3 (da) 2001-12-27
EP0467164A2 (de) 1992-01-22
HU912359D0 (en) 1991-12-30
LTIP919A (en) 1995-03-27
CN1070700C (zh) 2001-09-12
RU2070408C1 (ru) 1996-12-20
HRP920667B1 (en) 1998-06-30
EG19814A (en) 1996-02-29

Similar Documents

Publication Publication Date Title
MX9100160A (es) Procedimiento para preparar un medicamento que contiene flupirtina como sustancia activa para combatir contracturas musculares
DE3382458D1 (de) Haarwuchsmittel.
ES2064130T3 (es) Utilizacion de droloxifeno para el tratamiento de enfermedades de los huesos.
PT95826A (pt) Processo para a preparacao de composicoes farmaceuticas contendo como ingrediente activo acido r-alfa-liponico ou acido s-alfa-liponico
EP0444196A4 (en) Agent for treatment and prophylaxis of ischemic disease of heart or brain
ES513182A0 (es) "un procedimiento para preparar una composicion herbicida que contiene como ingrediente activo un derivado de acido hidroxamico".
HUT35659A (en) Process for producing 4-amino-methylene-chromane- and-chromene-derivatives and pharmaceutical compositions containing them as active agents
ES2088959T3 (es) 11-beta-aril-4-estreno, procedimiento para su preparacion y aplicacion como medicamento.
MX163574B (es) Procedimiento para preparar una composicion farmaceutica para inhalacion conteniendo un gangliosido
ATE325610T1 (de) Xanthinderivative zur behandlung von hirnischämie
ES8400742A1 (es) Procedimiento de preparacion de las dibenzooxepinas sustituidas y de sus sales de adicion con un acido mineral u organi-co.
AR004004A1 (es) Benzoilguanidinas sustituida, procedimiento para su preparacion, su utilizacion como medicamento o agente de diagnostico, asi como medicamento quelas contiene.
PT98532A (pt) Processo para a preparacao de formulacoes solidas para aplicacao oral contendo como ingrediente activo ifosfamida
NO873934L (no) Saarhelende serotoninantagonistisk forbindelse.
FR2401143A1 (fr) Nouvelles n-cyano-n'-(2-((4-methyl-5-imidazolyl) - methylthio)ethyl) - n''-alcynylguanidines, leur procede de preparation et medicament les contenant
PT97052A (pt) Processo para a preparacao de composicoes farmaceuticas contendo bambuterol, apropriadas para diminuir o teor de lipidos no sangue
JPS5753475A (en) Novel thiazolyl-2-oxamic acid derivative, manufacture and medicine containing same
FR2418218A1 (fr) Procede de preparation de pyrethrines et de leurs analogues et compositions insecticides qui les contiennent
ES2051839T3 (es) Un procedimiento para preparar tiadiazol-guanidinas.
IL87867A (en) Preparation of pharmaceutical compositions containing a 2,6-diamino-3-phenyl-azo-pyridine derivative
GR3037039T3 (en) Use of trimetazidine for the preparation of medicaments for the treatment of troubles due to the therapeutical use of immunosuppressants.
MX9302929A (es) Derivados de tetrahidro y perhidroisoquinolina y medios terapeuticos que los contienen.
SE9203296D0 (sv) The use of inositoltrisphate for the preparing of medicaments
UA26891C2 (uk) (s)-еhаhтіомер або рацемат похідhої 2-хлор-5-(2-хлор-4-трифторметилфеhокси)беhзоату, що має гербіцидhу активhість
ES473070A1 (es) Procedimiento para la obtencion de 2,3,4,7,8.9-octahidropi- razinopirimidinonas substituidas